Valuation: TFA Therapeutics, Inc.

Market Cap 578M 507M 479M 436M 817M 55.38B 823M 5.73B 2.22B 28.29B 2.17B 2.12B 90.93B P/E 2024
-4,052x
P/E 2025 -3,733x
Enterprise Value 578M 507M 479M 437M 818M 55.43B 823M 5.74B 2.22B 28.32B 2.17B 2.12B 91.01B EV / Sales 2024
732x
EV / Sales 2025 464x
Free-Float
16.44%
Yield 2024 *
-
Yield 2025 -
1 year 3.01
Extreme 3.01
6
3 years 0.04
Extreme 0.04
10.56
5 years 0.04
Extreme 0.04
10.56
10 years 0.04
Extreme 0.04
10.56
Manager TitleAgeSince
Chief Executive Officer 46 03/05/2020
Director TitleAgeSince
Director/Board Member 46 03/05/2020
Director/Board Member 54 30/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
+72.76%-.--%-43.36% - 578M
+1.60%+11.62%+14.86%+251.09% 388M
+0.45%+10.50%+29.24%+127.84% 154M
+1.30%+8.33%-35.80%-22.77% 156M
+5.36%+19.19%-3.28%-46.36% 120M
-0.12%+3.01%-32.16%-45.08% 65.2M
Average +13.56%+8.78%-11.75%+52.94% 243.43M
Weighted average by Cap. +29.83%+6.79%-15.64%+118.98%

Financials

2024 2025
Net sales 1.25M 1.1M 1.04M 947K 1.77M 120M 1.78M 12.43M 4.81M 61.38M 4.71M 4.6M 197M 1.25M 1.09M 1.03M 941K 1.76M 119M 1.77M 12.35M 4.78M 60.98M 4.68M 4.57M 196M
Net income -226K -199K -188K -171K -320K -21.69M -322K -2.24M -869K -11.08M -850K -831K -35.61M -155K -136K -128K -117K -219K -14.84M -220K -1.54M -595K -7.58M -581K -569K -24.36M
Net Debt 510K 448K 423K 386K 722K 48.93M 727K 5.06M 1.96M 25M 1.92M 1.88M 80.33M 475K 417K 394K 359K 672K 45.55M 677K 4.71M 1.83M 23.27M 1.78M 1.75M 74.78M
Logo TFA Therapeutics, Inc.
TFA Therapeutics, Inc., formerly Cordyceps Sunshine Biotech Holdings Co., Ltd., is a company mainly engaged in the research and development of novel nonsteroidal anti-inflammatory drugs. The Company uses antrocin A as its core candidate molecule to develop anti-inflammatory drugs with steroid replacement potential. Its main research project is TFA-01, currently targeting canine osteoarthritis as its primary indication, with plans to subsequently evaluate its applications in feline chronic dentistry and dermatitis. The Company has also established a bacterial strain development, culture amplification, and related technology platform to support the research and development of its candidate drugs.
Employees
-
  1. Stock Market
  2. Stocks
  3. RAJAF Stock